In human prostate cancer cells, CDDO-Me inhibits the activity of p-Akt and mTOR and of their downstream targets [51,52] and overexpression of Akt leads to resistance to CDDO-Me [52]. The gene discussed is AKT1; the disease is Familial prostate cancer.